Treatment of inflammatory bowel disease

被引：2

作者：

Nikolaus, S. ^{[1
]}

Schreiber, S. ^{[1
]}

机构：

[1] Univ Klinikum Schleswig Holstein, Klin Innere Med 1, D-24105 Kiel, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2013年 / 138卷 / 05期

关键词：

inflammatory bowel disease; Crohn's disease; ulcerative colitis; biologicals; CROHNS-DISEASE; ULCERATIVE-COLITIS; CLINICAL-COURSE; INFLIXIMAB; ADALIMUMAB; TRIAL; IBSEN;

D O I：

10.1055/s-0032-1327429

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：205 / 208

页数：4

共 14 条

[11]

Schreiber S, 2012, J CROHNS COLITIS

[12] Risk factors for opportunistic infections in patients with inflammatory bowel disease [J].

Toruner, Murat ;

Loftus, Edward V., Jr. ;

Harmsen, W. Scott ;

Zinsmeister, Alan R. ;

Orenstein, Robert ;

Sandborn, William J. ;

Colombel, Jean-Frederic ;

Egan, Laurence J. .

GASTROENTEROLOGY, 2008, 134 (04) :929-936

[13] Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial [J].

Van Assche, Gert ;

Vermeire, Severine ;

Ballet, Vera ;

Gabriels, Frederik ;

Noman, Maja ;

D'Haens, Geert ;

Claessens, Christophe ;

Humblet, Evelien ;

Casteele, Niels Vande ;

Gils, Ann ;

Rutgeerts, Paul .

GUT, 2012, 61 (02) :229-234

[14] Hitting a complex target: an update on interleukin-6 trans-signalling [J].

Waetzig, Georg H. ;

Rose-John, Stefan .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (02) :225-236

← 1 2 →